BELHAVEN BIOPHARMA
Belhaven Biopharma is a clinical trial material scale-up and production, IND preparation and filing, and a pilot human clinical trial for its dry powder intranasal epinephrine for treatment of anaphylaxis
BELHAVEN BIOPHARMA
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2021-01-01
Address:
Raleigh, North Carolina, United States
Country:
United States
Website Url:
http://www.belhavenbio.com
Total Employee:
1+
Status:
Active
Total Funding:
750 K USD
Similar Organizations
Invitek
Invitek is a preclinical CRO that offers a wide range of pre-clinical solutions for novel medication screening and evaluation of drugs.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sprout Pharmaceuticals
Sprout Pharmaceuticals is a medical company that develops products for the treatment of female sexual dysfunction.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
VitalTrax
VitalTrax connects patients with clinical trials with its cloud-based clinical trial network.
Investors List
North Carolina Biotechnology Center
North Carolina Biotechnology Center investment in Debt Financing - Belhaven Biopharma
North Carolina Biotechnology Center
North Carolina Biotechnology Center investment in Debt Financing - Belhaven Biopharma
Official Site Inspections
http://www.belhavenbio.com
- Host name: 112.0.153.160.host.secureserver.net
- IP address: 160.153.0.112
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Belhaven Biopharma"
About - Belhaven Biopharma
Our Company History. Belhaven was founded in 2021 in Raleigh, North Carolina, with initial funding from local angels and support from the North Carolina Biotechnology Center.This funding enabled the initial formulation work to …See details»
Home | Belhaven Biopharma
Our approach to drug development. Belhaven Biopharma leverages its expertise in drug development and formulation with its patented technology to expand patient access to …See details»
Belhaven Biopharma - Crunchbase Company Profile & Funding
Belhaven Biopharma is a clinical trial material scale-up and production, IND preparation and filing, and a pilot human clinical trial for its dry powder intranasal epinephrine for treatment of …See details»
Belhaven Biopharma - LinkedIn
Introducing a Seasoned Regulatory Leader to Belhaven! We’re pleased to announce that Lynn Gold, Ph.D., has joined Belhaven Biopharma as our new Head of Regulatory Affairs.Lynn brings with her 35 ...See details»
Belhaven Biopharma Inc. | North Carolina Biotech Center
Belhaven Biopharma is developing dry powder nasal products for a variety of indications.See details»
Our Focus | Belhaven Biopharma
Belhaven Biopharma Product Development. Belhaven is developing a pipeline of emergency use dry powder nasal products to better address the needs of patients and caregivers across a wide range of diseases.See details»
Belhaven Biopharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Feb 16, 2023: Debt Financing - …See details»
Belhaven Biopharma - PitchBook
Belhaven Biopharma General Information Description. Developer of a life-saving medication intended for the treatment of anaphylaxis. The company is developing a portfolio of dry powder …See details»
Belhaven Biopharma Achieves Significant Milestones in ... - Newswire
RALEIGH, N.C., November 28, 2023 (Newswire.com) - Belhaven Biopharma, a pioneering force in the development of emergency-use epinephrine for the 21st century, proudly announces …See details»
Belhaven Biopharma Achieves Significant Milestones in ... - BioSpace
Nov 28, 2023 Several key accomplishments completed to finish 2023 and create a strong foundation for 2024. RALEIGH, NC / ACCESSWIRE / November 28, 2023 / Belhaven …See details»
Belhaven Biopharma to Present Promising Phase 1 Data on Needle …
RALEIGH, N.C., October 24, 2024 (Newswire.com) - Belhaven Biopharma, a leader in nasal drug delivery technologies and emergency allergy care solutions, is set to present new clinical data …See details»
Scott Lyman - NAL Speakers Bureau
Scott Lyman, CEO and Co-Founder of Belhaven Biopharma, champions the mission of delivering accessible health care worldwide, with a particular focus on innovative allergy care.See details»
Scott Lyman | CEO - Belhaven Biopharma | Fast Company …
I have over 25 years of biopharmaceutical experience and have spent the last 10 years leading startups. My most recent role as the CEO of Belhaven is focused on making emergency …See details»
Contact - Belhaven Biopharma
To get in touch with Belhaven, email us using the form below. Name (Required). First LastSee details»
Belhaven Biopharma Announces Groundbreaking Clinical Results …
RALEIGH, N.C., February 8, 2024 (Newswire.com) - Belhaven Biopharma, a leader in innovative treatments for severe allergic reactions, today shared promising results from its Phase 1 …See details»
Belhaven Announces Milestones and Additions to Board
Nov 28, 2023 Significant milestones achieved in 2023 leading into 2024. First-in-human study initiated. Series A funding round opening.See details»
Scott Lyman on LinkedIn: Scott Lyman (Co-Founder and CEO, …
Vaccines Market Size And Forecast Vaccines Market size is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecast period from 2024–2031.See details»
News - Belhaven Biopharma
Stay up to date with news and announcements from Belhaven Biopharma.See details»
Belhaven Biopharma’s Nasdepi® Named Finalist for 2024 Fierce …
Oct 22, 2024 belhavenbio.com . Belhaven Biopharma 150 Fayetteville St , #2300 Raleigh, NC 27601 . Contacts. Janie Mackenzie. Vice President of Public Relations. janie@ ...See details»
Privacy Policy | Belhaven Biopharma
Who we are Our website address is: https://belhavenbio.com/ Comments When visitors leave comments on the site we collect the data shown in the comments form, and also ...See details»